Ozempic litigation has surged in recent months, with plaintiffs accusing Novo Nordisk of failing to adequately warn users about the drug’s severe side effects. They claim the company was aware, or should have been aware, of adverse events linked to Ozempic, such as gastroparesis (paralyzed stomach), uncontrollable vomiting, thyroid tumors, and gallbladder disease, yet delayed updating the drug’s warning label to reflect these risks.
Multidistrict Litigation (MDL)
As of December 2024, over 1,300 lawsuits have been consolidated into a federal multidistrict litigation (MDL-3094) in the Eastern District of Pennsylvania, presided over by Judge Gene Pratter. The MDL allows for streamlined legal proceedings, as plaintiffs nationwide report similar health issues caused by Ozempic.
Lawsuit Claims
The lawsuits detail injuries like persistent nausea, gastrointestinal damage, and even life-threatening complications. For example, Juanita Gantt’s case—one of the first to spark this wave of litigation—claims that prolonged vomiting and gastroparesis necessitated her colon removal surgery.
Similar Drugs Under Scrutiny
Other Novo Nordisk drugs, such as Wegovy (also used for weight loss), have faced similar allegations. Plaintiffs argue that manufacturers prioritized profits over transparency, leaving users unaware of the risks associated with these medications.
These lawsuits aim to hold drug companies accountable for allegedly placing consumers at significant health risks.
1-800-870-8910